Research Article
Evidence for Seroprevalence in Human Localized Cutaneous Leishmaniasis Caused by Leishmania donovani in Sri Lanka
Table 2
Serological response according to different clinical features.
| Clinical feature and category | Seropositive patients (n) (% within category) | Seronegative patients (n) (% within category) | Total (n) (% within category) |
| Originating province | | | | Northern | 6 (42.9%) | 8 (57.1%) | 14 (100%) | Southern | 9 (36.0%) | 16 (64.0%) | 25 (100%) | Other | 2 (18.2%) | 9 (81.8%) | 11 (100%) | Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) | Occupation | | | | Military | 6 (30.0%) | 14 (70.0%) | 20 (100%) | Civilian | 11 (39.3%) | 17 (60.7%) | 28 (100%) | Total | 17 (35.4%) | 31 (64.6%) | 48 (100%) | Age | | | | Up to 20 years | 3 (37.5%) | 5 (62.5%) | 8 (100%) | 21–40 years | 9 (39.1%) | 14 (60.9%) | 23 (100%) | >41 years | 5 (26.3%) | 14 (73.7%) | 19 (100%) | Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) | Sex | | | | Male | 13 (32.5%) | 27 (67.5%) | 40 (100%) | Female | 4 (40.0%) | 6 (60.0%) | 10 (100%) | Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) | Number of lesions | | | | Single | 14 (37.8%) | 23 (62.2%) | 37 (100%) | Multiple | 3 (23.1%) | 10 (76.9%) | 13 (100%) | Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) | Size of the lesions | | | | Up to 2 cm | 14 (46.7%) | 25 (53.3%) | 39 (100%) | >2 cm | 3 (27.2%) | 8 (72.8%) | 11 (100%) | Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) | Duration | | | | Up to 3 months | 4 (30.8%) | 9 (69.2%) | 13 (100%) | 3–6 months | 7 (36.8%) | 12 (63.2%) | 19 (100%) | 7–9 months | 2 (28.6%) | 5 (71.4%) | 7 (100%) | 10–12 months | 4 (36.4%) | 7 (63.6%) | 11 (100%) | Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) | Type of lesion | | | | Papule | 1 (25.0%) | 3 (75.0%) | 4 (100%) | Nodule | 8 (47.1%) | 9 (52.9%) | 17 (100%) | Ulcerating nodule | 4 (30.8%) | 9 (69.2%) | 13 (100%) | Ulcer | 3 (30.0%) | 7 (70.0%) | 10 (100%) | Plaque | 1 (16.7%) | 5 (83.3%) | 11 (100%) | Total | 17 (34.0%) | 33 (66.0%) | 50 (100%) |
|
|
Missing cases excluded.
|